Sembrix tablets 40mg, manufactured by Novartis Pharma, contains Asciminib Hydrochloride (YJ code: 4291077F2023, standard: 40mg 1 tablet). This allosteric inhibitor specifically targets the ABL myristoyl pocket of the BCR-ABL1 protein, providing a novel mechanism to overcome resistance in chronic myeloid leukemia (CML). It is used for Philadelphia chromosome-positive (Ph+) CML in chronic phase, including patients with the T315I mutation.
Sembrix tablets 40mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
